Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.

Cancer cell - 10 Jun 2024

Perurena Naiara, Cichowski Karen

Abstract excerpt

The development of mutant-selective KRAS inhibitors represents a major therapeutic advance; however, patients can develop resistance through feedback mechanisms and genetic alterations in the RAS pathway. Three publications in Nature and Cancer Discovery describe a promising RAS(ON) multi-selective inhibitor that simultaneously targets oncogenic RAS and multiple potential resistance mechanisms while sparing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Signal Transduction

Source

Identifiers

PMID: 38861932
DOI: 10.1016/j.ccell.2024.05.020

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.PMID 38861932Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Emerging landscape of KRAS inhibitors in cancer treatment.Semantic proximity Read ↗

Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.Semantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.Semantic proximity Read ↗

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies.Semantic proximity Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Drugging the Undruggable: Advances on RAS Targeting in Cancer.Semantic proximity Read ↗

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Semantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

The current state of the art and future trends in RAS-targeted cancer therapies.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.